FDA Daily Drug Adverse Event Reports
- The Food and Drug Administration (FDA) announced today, August 22, 2025, a significant shift in how it shares details about potential drug and biological product side effects.
- This change addresses long-standing concerns about the timeliness of safety information available to healthcare professionals and the public.
- The move reflects a broader commitment to enhancing post-market safety surveillance, a priority for Commissioner Makary.
FDA Dramatically increases Clarity of Drug Safety Reports
Table of Contents
Faster Access to Critical Safety Data
The Food and Drug Administration (FDA) announced today, August 22, 2025, a significant shift in how it shares details about potential drug and biological product side effects. The agency will now publish reports submitted through the FDA Adverse Event Reporting System (FAERS) on a daily basis, a marked improvement from the previous quarterly updates.
This change addresses long-standing concerns about the timeliness of safety information available to healthcare professionals and the public. As FDA Commissioner Marty Makary stated, “People who navigate the government’s clunky adverse event reporting websites shoudl not have to wait months for that information to become public. We’re closing that waiting period and will continue to streamline the process from start to finish.”
A Focus on Proactive Safety Surveillance
The move reflects a broader commitment to enhancing post-market safety surveillance, a priority for Commissioner Makary. He has consistently emphasized the importance of leveraging electronic health records to identify safety signals and assess the real-world effectiveness of medical products. This proactive approach aims to detect and address potential problems more quickly than relying solely on traditional reporting methods.
Health Secretary Robert F. Kennedy Jr. has also voiced support for strengthening the agency’s surveillance capabilities, particularly concerning vaccines, a topic he has frequently discussed throughout his career. While his focus has often been on vaccine safety, the broader goal of improved monitoring aligns with the FDA’s new initiative.